LAURA LAROSE: Open Payments
NPI 1538687462 · SANTA MONICA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,883 in 31 payments from 11 companies in 2025. Trend: 2023 $2,477 · 2024 $3,432 · 2025 $1,883
Long term medical supply or device loan: $1,000Food & beverage: $803Education: $80
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 12 | $1,000 |
| Janssen Biotech, Inc. | 2 | $217 |
| AstraZeneca Pharmaceuticals LP | 3 | $212 |
| Astellas Pharma US Inc | 1 | $130 |
| Caris MPI, Inc. | 3 | $90 |
| Celgene Corporation | 3 | $73 |
| Gilead Sciences, Inc. | 2 | $49 |
| Merck Sharp & Dohme LLC | 2 | $49 |
| ARRAY BIOPHARMA INC | 1 | $28 |
| Stemline Therapeutics Inc. | 1 | $20 |
Products named: KISQALI, RYBREVANT, Vyloy, MI CANCER SEEK, ERLEADA, REBLOZYL, Trodelvy, KEYTRUDA.
Industry payments across CA — which companies pay providers there.
